Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439183 | 0.88 | NPC1 (0.38) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1402228 | 0.84 | DRD2 (0.47) | MCL1HTR1AOPRK1 | |
| SCHEMBL3593984 | 0.76 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22368762 | 0.75 | MAPT (0.49) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3212830 | 0.74 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL98299 | 0.74 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2234486 | 0.74 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL837526 | 0.74 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3723532 | 0.74 | SRD5A1 (0.57) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL18885726 | 0.74 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2701512-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| WO-2012148808-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | NPC1 2922/4885MAPK13 1055/4885MAPK12 1147/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | NPC1 2922/4885MAPK13 1055/4885MAPK12 1147/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | NPC1 1135/4885MAPK13 1262/4885MAPK12 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.